Cargando…

The generation and analysis of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic

Detalles Bibliográficos
Autores principales:	Tsang, Kwong Y, Gabitzsch, Elizabeth S, Palena, Claudia, David, Justin M, Fantini, Massimo, Kwilas, Anna R, Rice, Adrian E, Latchman, Yvette, Hodge, James W, Jochems, Caroline, Fernando, Romaine I, Gulley, James, Madan, Ravi A, Heery, Christopher R, Balint, Joseph P, Jones, Frank R, Schlom, Jeffrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652550/ http://dx.doi.org/10.1186/2051-1426-3-S2-P452

Ejemplares similares

The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic
por: Gabitzsch, Elizabeth S., et al.
Publicado: (2015)

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
por: Jochems, Caroline, et al.
Publicado: (2016)

Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells
por: Lepone, Lauren, et al.
Publicado: (2015)

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
por: Donahue, Renee N., et al.
Publicado: (2017)

Treatment with the IDO inhibitor INCB024360 increased lysis of human tumor cell targets by peptide-specific CTL
por: Jochems, Caroline, et al.
Publicado: (2015)

Investigation of antibody dependent cellular cytotoxicity as a mechanism of action for a novel anti-PD-L1 monoclonal antibody
por: Boyerinas, Benjamin, et al.
Publicado: (2014)

Impact of androgen deprivation therapy on the thymus and the production of naïve T-cells
por: Madan, Ravi A, et al.
Publicado: (2013)

Digital immunohistochemistry analysis of intratumoral immune infiltrates in prostate cancer patients treated with intraprostatic/systemic PSA-TRICOM vaccine
por: Farsaci, Benedetto, et al.
Publicado: (2013)

Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer
por: Tucker, Jo A., et al.
Publicado: (2012)

An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression
por: Rice, Adrian E, et al.
Publicado: (2015)

Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses
por: Heery, Christopher R, et al.
Publicado: (2015)

An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition
por: Palena, Claudia, et al.
Publicado: (2014)

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
por: Lind, Hanne, et al.
Publicado: (2020)

Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity
por: Madan, Ravi A, et al.
Publicado: (2012)

Poxviral-based vaccine elicits immunologic responses in prostate cancer patients
por: Madan, Ravi A, et al.
Publicado: (2014)

Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab
por: Fujii, Rika, et al.
Publicado: (2016)

Identification and characterization of agonist epitopes of the MUC1-C oncoprotein
por: Jochems, Caroline, et al.
Publicado: (2013)

Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival
por: Grenga, Italia, et al.
Publicado: (2013)

Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression
por: Grenga, Italia, et al.
Publicado: (2015)

PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients
por: Lepone, Lauren, et al.
Publicado: (2014)

Impact of age on antigen-specific T lymphocyte response in patients treated with PSA-TRICOM
por: Singh, Harpreet, et al.
Publicado: (2014)

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
por: Bilusic, Marijo, et al.
Publicado: (2019)

Generation of human T cells directed against an agonist epitope of Brachyury, a transcription factor involved in human tumor cell epithelial to mesenchymal transition (EMT)
por: Boyerinas, Benjamin, et al.
Publicado: (2013)

Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine
por: Hamilton, Duane H., et al.
Publicado: (2013)

The role of soluble CD40L in immunosuppression
por: Schlom, Jeffrey, et al.
Publicado: (2013)

The Use of a Humanized NSG-β2m(−/−) Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa
por: Morillon, Y. Maurice, et al.
Publicado: (2020)

Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301)
por: Donahue, Renee N, et al.
Publicado: (2014)

Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types
por: Lepone, Lauren M., et al.
Publicado: (2016)

Exploiting Synergy: Immune-Based Combinations in the Treatment of Prostate Cancer
por: Burotto, Mauricio, et al.
Publicado: (2014)

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer
por: Gatti‐Mays, Margaret E., et al.
Publicado: (2019)

Aberrant expression of the embryonic transcription factor brachyury in human tumors detected with a novel rabbit monoclonal antibody
por: Hamilton, Duane H., et al.
Publicado: (2014)

Multi-spectral immunofluorescence evaluation of the myeloid, T cell, and natural killer cell tumor immune microenvironment in chordoma may guide immunotherapeutic strategies
por: Lopez, Diana C., et al.
Publicado: (2022)

A poxviral-based cancer vaccine targeting the transcription factor Twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer model
por: Kwilas, Anna R., et al.
Publicado: (2015)

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
por: Hicks, Kristin C., et al.
Publicado: (2018)

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)
por: Bilusic, Marijo, et al.
Publicado: (2021)

Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009
por: Pellom, Samuel T., et al.
Publicado: (2021)

Brachyury, a driver of tumor invasiveness and resistance to multiple therapies, is a novel immunotherapy target
por: Palena, Claudia, et al.
Publicado: (2013)

High levels of expression of the transcription factor Brachyury induce resistance of human carcinoma cells to immune-mediated attack
por: Hamilton, Duane H, et al.
Publicado: (2013)

Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer
por: DeMaria, Peter J, et al.
Publicado: (2021)

Novel adenoviral serotype 5 based immunotherapeutic induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients
por: Morse, Michael, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_iec5p4vjq8cm8m0us5ds6drc3a